Results 1 to 10 of about 31,486 (223)

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study [PDF]

International Journal of Infectious Diseases, 2021
Objective: The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy.
A. Balkhair, I. Al-Zakwani, M. Al Busaidi, A. Al-Khirbash, S. Al Mubaihsi, H. BaTaher, J. Al Aghbari, I. Al Busaidi, M. Al Kindi, S. Baawain, A. Al Alawi, A. Al Lawati, B. Al Rawahi, K. Al-Baimani, K. Al Zidi, N. Elfatih, B. Dawud, B. John, F. Rehman, F. Yousif, G. Al Khadouri, I. Saber, J. Lal, M. Gargouri, M. Al-Ward, N. AbuDraz, S. Al Ruqeishi, S. Kumar, W. Abdelmottaleb, Z. Al-Naamani, Z. Bin Nazar, O. Balkhair   +31 more
doaj   +2 more sources

The Effect of Anakinra on Acrylamide-induced Peripheral Neuropathy and Neuropathic Pain in Rats

Brazilian Journal of Pharmaceutical Sciences, 2023
Acrylamide is a neurotoxic compound. Moreover, anakinra is an interleukin-1 (IL-1) receptor antagonist used in rheumatoid arthritis treatment. This study investigated the effect of anakinra on acrylamide-related neuropathy and neuropathic pain ...
Alevtina Ersoy, Ceyda Tanoglu, Gulce Naz Yazici, Taha Abdulkadir Coban, Renad Mammadov, Halis Suleyman   +5 more
doaj   +2 more sources

Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis

Critical Care Explorations, 2023
OBJECTIVES:. Patients with sepsis are at significant risk for multiple organ dysfunction, including the lungs and kidneys. To manage the morbidity associated with kidney impairment, continuous renal replacement therapy (CRRT) may be required.
Samuel D.J. Dubinsky, PharmD, Kevin M. Watt, MD, PhD, Carina E. Imburgia, BSc, Autumn M. Mcknite, BSc, J. Porter Hunt, PhD, Cassandra Rice, PhD, Joseph E. Rower, PhD, DABCP, Andrea N. Edginton, PhD   +7 more
doaj   +2 more sources

Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report [PDF]

Clinical Case Reports, 2020
The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.
Leonard Kaps, Christian Labenz, Daniel Grimm, Andreas Schwarting, Peter R. Galle, Oliver Schreiner   +5 more
doaj   +2 more sources

Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature [PDF]

Mediators of Inflammation, 2015
Background. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients. Methods.
A. Aouba, S. Deshayes, L. Frenzel, A. Decottignies, C. Pressiat, B. Bienvenu, F. Boue, G. Damaj, O. Hermine, S. Georgin-Lavialle   +9 more
doaj   +8 more sources

Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra. [PDF]

Circ Heart Fail
Van Tassell BW, Golino M, Canada JM, Markley R, Billingsley H, Del Buono M, Talasaz A, Thomas G, Chiabrando JG, Wohlford G, Dickson V, Kadariya D, Damonte JI, Ho AJ, Sedhai YR, Kontos E, Vecchiè A, West JD, Corna G, Medina de Chazal H, Pinel S, Bressi E, Barron A, Dell M, Mbualungu J, Moroni F, Turlington J, Federmann E, Trankle C, Carbone S, Arena R, Abbate A.   +31 more
europepmc   +3 more sources

The Endogenous Th17 Response in NO2-Promoted Allergic Airway Disease Is Dispensable for Airway Hyperresponsiveness and Distinct from Th17 Adoptive Transfer [PDF]

, 2013
Severe, glucocorticoid-resistant asthma comprises 5-7% of patients with asthma. IL-17 is a biomarker of severe asthma, and the adoptive transfer of Th17 cells in mice is sufficient to induce glucocorticoid-resistant allergic airway disease.
A Abe, A Duguet, A Hoshino, A Vazquez-Tello, A Vazquez-Tello, AG Besnard, AG Besnard, AI Caceres, AJ Coyle, AR Brasier, AR Sousa, AS Saffar, AT Hastie, B Korkmaz, Benjamin T. Suratt, BJ Canning, C Sutton, C Taube, D Stejskal, Daniel J. Weiss, DB Corry, DC Newcomb, DC Newcomb, DC Newcomb, DH Broide, E Goleva, F Kirstein, GJ Zijlstra, H Fujie, H Koga, H Wakashin, Hong Wei Chu, I Tillie-Leblond, J Agbetile, J Chang, J Seok, J Sunyer, J Zhao, JB Cowland, Jennifer L. Ather, JH Bates, JH Lee, JL Ather, JL Ather, John F. Alcorn, JR Karlsen, JV Fahy, K Raemdonck, K Yang, L McKinley, LA Cooney, Laura Hoyt, Lennart K. A. Lundblad, LJ Akinbami, LK Lundblad, LK Lundblad, LK Lundblad, LL Reber, M Bevelander, M Kawaguchi, M Kudo, M Leppkes, M Suzukawa, MA Willart, Matthew E. Poynter, ME Poynter, ME Poynter, ME Poynter, MH Brutsche, MH Shaw, MW Kinyanjui, N Schmitz, PA Wark, PL Delamater, PS Foster, PW Hellings, Q Wang, R He, RA Martin, Rebecca A. Martin, Rebecca Daggett, RH Wilson, S Ano, S Dragon, S Ferretti, S Haak, S Lajoie, S Molet, S Schnyder-Candrian, S Suzuki, S Wenzel, SJ Ballantyne, SM Hu, SP Chapoval, SR Hodgkins, T Li, VJ Johnson, W Al-Ramli, WP Arend, WW Lee, X Yao, XY Chi, Y Chung, Y Liu, Y Takenoue, Y Zhao, YH Wang   +106 more
core   +21 more sources

Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.

PLoS ONE, 2022
ObjectiveWe aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients.MethodsIn this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen.
Alexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, Johan Courjon, Vincent Langlois, Marc-Olivier Vareil, Mathilde Devaux, Boris Bienvenu, Vincent Leroy, Radjiv Goulabchand, Léa Colombain, Adrien Bigot, Thomas Guimard, Youcef Douadi, Geoffrey Urbanski, Jean François Faucher, Laurence Maulin, Bertrand Lioger, Jean-Philippe Talarmin, Matthieu Groh, Joseph Emmerich, Sophie Deriaz, Nicole Ferreira-Maldent, Ann-Rose Cook, Céline Lengellé, Hélène Bourgoin, Arsène Mekinian, Achille Aouba, François Maillot, Agnès Caille   +29 more
doaj   +2 more sources

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study

Pediatric Rheumatology Online Journal, 2023
Background and objective Evidence for the treatment of multisystem inflammatory syndrome in children (MIS-C) is lacking. Anakinra, which targets IL-1-mediated inflammation, is reserved for refractory cases of MIS-C; however, its use in the treatment of ...
Brian L.P. Dizon, Christopher Redmond, Emily C. Gotschlich, Sangeeta Sule, Tova Ronis, Kathleen M. Vazzana, Matthew A. Sherman, Rachael Connor, Abigail Bosk, Niti Dham, Ashraf S. Harahsheh, Elizabeth Wells, Roberta DeBiasi, Hemalatha Srinivasalu   +13 more
doaj   +1 more source

Intravenous administration of anakinra in children with macrophage activation syndrome

Pediatric Rheumatology Online Journal, 2021
Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related ...
Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad   +4 more
doaj   +1 more source